Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)

Detalles Bibliográficos
Autores principales: Brahmer, Julie, Balmanoukian, Ani, Goldberg, Sarah, Ou, Sai-Hong, Blake-Haskins, Andrew, Karakunnel, Joyson, Stockman, Paul, Rizvi, Naiyer, Antonia, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288573/
http://dx.doi.org/10.1186/2051-1426-2-S3-P179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288573/
http://dx.doi.org/10.1186/2051-1426-2-S3-P179

Ejemplares similares